Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

WA biotech duo takes aim at diabetes beyond Ozempic

Summary by The West Australian
A WA biotech duo ProGenis and Syngenis Laboratories is chasing the next frontier in diabetes medicine, developing RNA-based therapies targeting insulin resistance while building Australia’s first RNA facility.

3 Articles

The AgeThe Age
+2 Reposted by 2 other sources
Lean Left

WA biotech duo takes aim at diabetes beyond Ozempic

A WA biotech duo, ProGenis and Syngenis Laboratories, is developing RNA-based therapies at the next frontier in diabetes medicine, while building Australia’s first RNA facility.

·Australia
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources lean Left, 50% of the sources lean Right
50% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Age broke the news in Australia on Thursday, May 7, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Diabetes icon

Diabetes

Ozempic icon

Ozempic

Western Australia icon

Western Australia

Health & Medicine icon

Health & Medicine

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal